Completion pneumonectomy for chronic mycobacterial disease.

OBJECTIVE: Patients with persistent pulmonary infections from mycobacterial disease present a difficult clinical challenge. These individuals typically have poor pulmonary function, malnutrition, and other comorbidities, and few guidelines exist regarding optimal therapy. We report our experience with completion pneumonectomy as part of a multidisciplinary treatment program for patients with recurrent, persistent mycobacterial disease. METHODS: During a 9-year period, 26 consecutive patients underwent completion pneumonectomy for mycobacterial disease. All patients underwent intensive, guided preoperative antibiotic therapy and aggressive nutritional supplementation. Complete surgical resection of the remaining destroyed or infected lung tissue was performed, often through an extrapleural dissection with intrapericardial ligation of vessels. Vascularized tissue flaps were used whenever possible to buttress the bronchial stump closure. Postoperative management consisted of a multidisciplinary approach, with ongoing antibiotic and nutritional therapy. RESULTS: The primary organisms were Mycobacterium avium complex (n = 15), Mycobacterium tuberculosis (n = 5), Mycobacterium abscessus (n = 3), Mycobacterium xenopi (n = 2), and Mycobacterium chelonae (n = 1). Operative mortality was 23% (6/26): respiratory failure or adult respiratory distress syndrome in 2 cases, sepsis in 2, bronchopleural fistula in 1, and pulmonary embolism in 1. Significant morbidity occurred in 46% (12/26). Among the 17 long-term survivors, sputum conversion or discontinuation of medications was achieved in 14 (82%). Mean length of follow-up was 45 months (range 4-105 months). CONCLUSION: Completion pneumonectomy remains an important component of therapy in patients with mycobacterial disease who have had failure of previous therapy. Although associated with significant risks, successful outcomes can be achieved with an organized, multidisciplinary approach and careful postoperative follow-up.

Circulatory benefits of diastolic counterpulsation in an ischemic heart failure model after aortomyoplasty.

OBJECTIVE: Aortomyoplasty is an experimental surgical procedure in which the latissimus dorsi muscle is wrapped around the thoracic aorta and stimulated to contract during diastole, providing diastolic counterpulsation. We hypothesized that aortomyoplasty could improve cardiac function in a chronic ischemic heart failure model, similar to the improvement seen with the intra-aortic balloon pump. METHODS: Six dogs (25-30 kg) successfully underwent aortomyoplasty followed by serial coronary microembolization. Ejection fraction decreased from 63.5% to 36.5%. Two weeks after the final microembolization, the muscle was conditioned for 4 months to achieve fatigue resistance. One year after aortomyoplasty, hemodynamic studies during 1 hour of aortomyoplasty and 1 hour of intra-aortic balloon counterpulsation determined mean diastolic aortic pressure, peak left ventricular pressure, and endocardial viability ratio for assisted and unassisted beats. Cardiac output, stroke volume, and parameters of cardiac function were also measured. RESULTS: Endocardial viability ratio increased by 23.8% +/- 7.9% (P =.001) with aortomyoplasty counterpulsation and by 22.7% +/- 12.9% (P =.021) with the intra-aortic balloon pump. Both aortomyoplasty and the intra-aortic balloon pump significantly increased mean diastolic aortic pressure and reduced peak left ventricular pressure. Improvements in cardiac function with aortomyoplasty and the intra-aortic balloon pump were similar. Cardiac output increased from 2.61 +/- 0.88 to 3.07 +/- 1.06 L/min (P =.006), and index of afterload decreased from 5.4 +/- 1.4 to 4.8 +/- 1.4 mm Hg/mL (P =.02) during 1 hour of aortomyoplasty counterpulsation. CONCLUSION: One year after the procedure, aortomyoplasty counterpulsation provided diastolic augmentation and improved cardiac performance similar to the improvement provided by the intra-aortic balloon pump in a chronic ischemic heart failure model. Aortomyoplasty has the potential to benefit patients with ischemic heart disease refractory to current therapies.

Axillary artery cannulation for cardiopulmonary bypass reduces cerebral microemboli.

BACKGROUND: Aortic cannulation for cardiopulmonary bypass (CPB) is linked to cerebral microemboli emanating from the ascending aorta. Aortic calcification or disease requiring replacement precludes aortic cannulation. Clinical experience with axillary artery cannulation led to the hypothesis that axillary cannulation may be cerebroprotective. METHODS: Five mongrel dogs underwent a median sternotomy and isolation of the right axillary artery. The canine bicarotid brachiocephalic trunk was reconfigured by grafting the origin of the left carotid to the proximal left subclavian artery. Microspheres were injected into the ascending aorta during 4 conditions: before and after reconfiguration, CPB with aortic cannulation, and CPB with axillary cannulation. Brain, kidneys, and skeletal muscle were analyzed for microsphere distribution. RESULTS: Each animal served as its own control for comparison of aortic and axillary cannulation. No significant differences were documented in microsphere deposition for prereconfiguration and postreconfiguration. In the right middle cerebral artery distribution, 2300 +/- 710 microspheres per gram were deposited during aortic cannulation, compared with 540 +/- 110 during axillary cannulation (P <.05). In the left middle cerebral artery region, 2030 +/- 330 microspheres per gram with aortic cannulation were reduced to 1320 +/- 240 with axillary cannulation (P <.05). Axillary cannulation resulted in 73% fewer microspheres in the right brain and 40% fewer microspheres in the left compared with aortic cannulation (P <.05). CONCLUSIONS: Axillary artery cannulation for CPB is cerebroprotective. Altered blood-flow patterns during axillary cannulation may produce retrograde brachiocephalic artery blood flow and competing intracerebral right-to-left collateral blood flow, deflecting emboli from the ascending aorta and arch toward the descending aorta. Expanded use of axillary artery cannulation during cardiac operations could decrease the incidence of stroke.

Long-term survival outcomes by smoking status in surgical and nonsurgical patients with non-small cell lung cancer: comparing never smokers and current smokers.

BACKGROUND: Survival outcomes of never smokers with non-small cell lung cancer (NSCLC) who undergo surgery are poorly characterized. This investigation compared surgical outcomes of never and current smokers with NSCLC. METHODS: This investigation was a single-institution retrospective study of never and current smokers with NSCLC from 1975 to 2004. From an analytic cohort of 4,546 patients with NSCLC, we identified 724 never smokers and 3,822 current smokers. Overall, 1,142 patients underwent surgery with curative intent. For survival analysis by smoking status, hazard ratios (HRs) were estimated using Cox proportional hazard modeling and then further adjusted by other covariates. RESULTS: Never smokers were significantly more likely than current smokers to be women (P < .01), older (P < .01), and to have adenocarcinoma (P < .01) and bronchioloalveolar carcinoma (P < .01). No statistically significant differences existed in stage distribution at presentation for the analytic cohort (P = .35) or for the subgroup undergoing surgery (P = .24). The strongest risk factors of mortality among patients with NSCLC who underwent surgery were advanced stage (adjusted hazard ratio, 3.43; 95% CI, 2.32-5.07; P < .01) and elevated American Society of Anesthesiologists classification (adjusted hazard ratio, 2.18; 95% CI, 1.40-3.40; P < .01). The minor trend toward an elevated risk of death on univariate analysis for current vs never smokers in the surgically treated group (hazard ratio, 1.20; 95% CI, 0.98-1.46; P = .07) was completely eliminated when the model was adjusted for covariates (P = .97). CONCLUSIONS: Our findings suggest that smoking status at time of lung cancer diagnosis has little impact on the long-term survival of patients with NSCLC, especially after curative surgery. Despite different etiologies between lung cancer in never and current smokers the prognosis is equally dismal.

Are surgical outcomes for lung cancer resections improved at teaching hospitals?

BACKGROUND: Defining centers of excellence for complex surgical procedures, including pulmonary resection, reveals lower mortality at high-volume centers. We postulate that short-term outcome after lung cancer resection is better at teaching hospitals (TH) compared with nonteaching hospitals (non-TH), independent of volume. METHODS: Lung cancer resections in the Nationwide Inpatient Sample (NIS) dataset from 1998 to 2004 were stratified by resection type (segmentectomy, lobectomy, and pneumonectomy). The TH identified in the NIS include those with Accreditation Council for Graduate Medical Education-approved general surgery (GSTH) and thoracic surgery (TSTH) residency programs. The association of hospital teaching status with in-hospital mortality was assessed by multivariate logistic regression, adjusting for patient demographics and comorbidities. RESULTS: Of 46,951 lung resections (5,651 segmentectomies, 37,027 lobectomies, 4,273 pneumonectomies), 56% were performed at TH. Overall mortality was significantly lower at TH versus non-TH (3.2% vs 4.0%; p < 0.001). Subgroup analysis for GSTH and TSTH confirmed this decrease. On multivariate regression, overall odds of death was independently reduced by 17% at TH versus non-TH (95% confidence interval: 0.73 to 0.93; p = 0.002). At TH, odds of death for pneumonectomy and lobectomy were significantly reduced independent of surgical volume, except for the latter at the highest hospital volume strata. CONCLUSIONS: In-hospital mortality is reduced for patients undergoing lung cancer resections at teaching hospitals, with results prominent at all but the highest volume institutions. Lower mortality rates persisted at GSTH and TSTH. Understanding and disseminating the processes of care associated with these settings may improve quality of care for lung cancer patients, and decrease patient bias against teaching hospitals.

Lung cancer: new surgical approaches.

Over the past two decades, many surgical specialties have seen a dramatic shift from large, open operations with wide incisions towards more-minimal incisions and less-invasive procedures. Surgical techniques for lung cancer are no exception, and today, video-assisted thoracic surgical lobectomies are being performed with increasing frequency in large-volume thoracic practices. Despite these new surgical techniques, however, the most substantial innovations that have changed surgical outcomes occurred away from the operative theatre. In lung cancer, in particular, the last 20 years have witnessed the clinical debut of more sophisticated, more elegant and more accurate imaging modalities for improved screening, diagnostic and staging, such as the spiral CT scan, PET scan, PET/CT and the endobronchial ultrasound machine. This technology has been complimented by more targeted chemotherapeutic regimens, novel methods of administering more accurate and more concentrated doses of radiation therapy, and innovative local excisional methods, such as the Cyberknife and radiofrequency ablation. The result has been that surgical excision, although remaining the most effective local therapeutic modality in early-stage lung cancer, is no longer the 'lone ranger' treatment, but rather is part of a complex mosaic of multimodality therapy. As scientific advances continue to be translated into the clinic, this trend will inexorably continue with the advent of a molecular staging system using molecular markers and tumour profiling, which ultimately could enhance our ability to predict tumour chemosensitivity. In this brave new world, however, complete surgical resection of the lung cancer will continue to be critical.

Reducing Mortality Among Elderly Patients Undergoing Urgent Surgical Revascularization for Acute Myocardial Infarction.

INTRODUCTION: Elderly patients undergoing coronary bypass surgery after acute myocardial infarction represent a distinct, high risk subgroup. We sought to identify independent risk factors for mortality in a series of patients operated on in our hospital. METHODS: The case records of 499 consecutive patients greater than 70 years were identified, and 94 of these patients underwent urgent/emergent coronary bypass surgery within 7 days of acute myocardial infarction. Patients received either cold (4°C) or tepid (32°C) cardioplegia for myocardial protection. RESULTS: Mortality for the tepid cardioplegia group was 0/33, and the mortality for the cold cardioplegia group was 12/61 (0% vs. 20%, p equals 0.003). Multivariate analysis demonstrated left ventricular dysfunction and cold blood cardioplegia to be independent predictors of mortality. CONCLUSION: The type of myocardial protection technique is a significant predictor of mortality, and tepid cardioplegia may provide significant advantages to this high risk patient population.